Skip to content

A clinical study to evaluate Dermatitis Lotion for treatment of Atopic Dermatitis in Children

Evaluation of efficacy and safety of Dermatitis Lotion in the treatment of Atopic Dermatitis in Children: A prospective, single center, interventional study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/12/029971
Enrollment
35
Registered
2020-12-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

Intervention1: Dermatitis Lotion: The investigational product, Dermatitis Lotion is a nutraceutical product, formulated as a lotion which has Omega - 3 fatty acid oil (Seabuckthorn oil), Probiotic Lys

Sponsors

Amitojas Wellness Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male and female children aged >= 6 months to 2. Subject diagnosed with Atopic Dermatitis as per the medical judgement of the study investigator. 3. Subject with mild to severe eczema as determined by the Patient-Oriented Eczema Measure (POEM) score. 4. Children willing to provide informed assent if applicable. 5. Childâ??s parent/guardian/legally acceptable representative willing to provide informed written consent.

Exclusion criteria

Exclusion criteria: 1. Children with significant medical/surgical condition which requires long-term treatment. 2. Children with genetic diseases, congenital diseases and mentally challenged. 3. Children who are currently being treated with other atopic dermatitis drugs. 4. Subject has clinically infected atopic dermatitis at the time of screening. 5. Allergy or sensitivity to any of the ingredients in the study treatment. 6. Subjects who have participated in other clinical studies during the past 3 months or subjects who intend to participate in other clinical studies parallely. 7. Subjects with any other illness or health condition which in the opinion/medical judgement of the study investigator makes the subject ineligible to participate in the study.

Design outcomes

Primary

MeasureTime frame
Patient-Oriented Eczema Measure (POEM) score documented in the CRF baseline, day 30, day 60 and day 90Timepoint: baseline, day 30, day 60 and day 90

Secondary

MeasureTime frame
Skin Tone, Skin Texture and Moisturisation of Atopic Dermatitis affected areas documented in the CRF baseline, day 30, day 60 and day 90Timepoint: baseline, day 30, day 60 and day 90

Countries

India

Contacts

Public ContactMr Kamal Kammili

Amitojas Wellness Private Limited

cso@amitojas.com8885324455

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026